{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:17Z","timestamp":1793406917012,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ophtha.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T17:00:55Z","timestamp":1720630855000},"page":"1339-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma"],"prefix":"10.1016","volume":"131","author":[{"given":"Edward J.","family":"Wladis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Aakalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Reza","family":"Vagefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah P.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"McCulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne K.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.06.007_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A\u00a0systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/01676830.2016.1176210","article-title":"Orbital exenteration: the 10-year massachusetts eye and ear infirmary experience","volume":"35","author":"Nagendran","year":"2016","journal-title":"Orbit"},{"key":"10.1016\/j.ophtha.2024.06.007_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/SAP.0b013e31826a1a56","article-title":"Reconstruction of complex orbital exenteration defects: a single center\u2019s experience with a five-year follow-up","volume":"73","author":"Rabey","year":"2014","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ophtha.2024.06.007_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.devcel.2016.07.026","article-title":"Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy","volume":"38","author":"Pak","year":"2016","journal-title":"Dev Cell"},{"key":"10.1016\/j.ophtha.2024.06.007_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-019-00648-2","article-title":"Hedgehog pathway inhibition for the treatment of basal cell carcinoma","volume":"14","author":"Gutzmer","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/fon.14.281","article-title":"Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus","volume":"11","author":"Peris","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib8","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (bolt): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal Erivance BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ophtha.2024.06.007_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jdv.14542","article-title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 bolt study","volume":"32","author":"Lear","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","article-title":"Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial","volume":"138","author":"Ben Ishai","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2024.06.007_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41433-022-01982-y","article-title":"The initial rate of tumour response to vismodegib treatment can predict a complete response outcome for periocular LA-BCC","volume":"37","author":"Tiosano","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2024.06.007_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-10-5101-2","article-title":"Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases","volume":"5","author":"Wong","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.ophtha.2024.06.007_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","article-title":"Neoadjuvant vismodegib and Mohs micrographic surgery for locally advanced periocular basal cell carcinoma","volume":"35","author":"Gonzalez","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2024.06.007_bib16","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.1002\/onco.13820","article-title":"Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial","volume":"26","author":"Kahana","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ophtha.2024.06.007_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265212","article-title":"Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: follow up to the VISORB trial","volume":"17","author":"Unsworth","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2024.06.007_bib18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib19","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1038\/s41433-020-01291-2","article-title":"Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma","volume":"35","author":"Curragh","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2024.06.007_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (Erivedge) for basal cell carcinoma involving the orbit and periocular area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2024.06.007_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","article-title":"Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma","volume":"207","author":"Eiger-Moscovich","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib22","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41433-020-0778-3","article-title":"Vismodegib for periocular basal cell carcinoma: an international multicentre case series","volume":"34","author":"Oliphant","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2024.06.007_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","article-title":"Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome","volume":"160","author":"Ozgur","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IOP.0000000000001251","article-title":"Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2024.06.007_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","article-title":"Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma","volume":"103","author":"Sagiv","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/09546634.2020.1771262","article-title":"The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients","volume":"33","author":"Villani","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.ophtha.2024.06.007_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.abd.2021.04.012","article-title":"Vismodegib for treatment of periocular basal cell carcinoma\u20146-year experience from a tertiary cancer center","volume":"96","author":"Xavier","year":"2021","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib28","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s13555-023-00985-1","article-title":"The efficacy of sonidegib in treating locally advanced basal cell carcinoma involving the periocular area","volume":"13","author":"Villani","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ophtha.2024.06.007_bib29","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.18632\/oncotarget.28080","article-title":"Switching hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma","volume":"12","author":"Doan","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.ophtha.2024.06.007_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","article-title":"An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma","volume":"71","author":"Ally","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study","volume":"80","author":"Chang","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ophtha.2024.06.007_bib32","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024003609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024003609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:37:10Z","timestamp":1764121030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024003609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0161642024003609"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.06.007","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}